NXL PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

NXL ▼ -31.70% at T+20d

SHORT call ✓ call won +31.70% · α vs SPY +34.87% · entry $0.4700 → $0.3210

Next anchor: T+60d in 5w

Last close $0.5020 (close Jun 8) · -6.81% from $0.4700 entry (call sign-flipped)

Entry anchored
Apr 21, 03:59 PM ET
via Databento tick

T+1d

-8.30%

call +8.30% · α +7.90%

$0.4310

settled 7w ago

T+5d

-21.30%

call +21.30% · α +21.35%

$0.3699

settled 6w ago

T+20d

-31.70%

call +31.70% · α +34.87%

$0.3210

settled 21d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Nexalin Technology (NXL) reported a Q4 2025 EPS miss of -27% versus consensus, with actual EPS of -$0.13 versus an estimate of -$0.10. The company provided no revenue guidance and instead focused on advancing its HALO™ Clarity clinical trial for insomnia, marking a strategic pivot toward regulatory development rather than commercial performance.

Actionable Insight

The stock is likely to react negatively to the EPS miss and lack of revenue traction; monitor for trial enrollment updates as near-term catalysts, but expect continued pressure until meaningful revenue or funding milestones are achieved.

Key Facts

Q4 2025 EPS was -$0.13, missing consensus by -27% (estimated: -$0.10)
Reported revenue was $15K, though no actual revenue figure was disclosed in the release
No financial guidance or revenue updates were provided
Company is advancing a pivotal clinical trial for its HALO™ Clarity device targeting FDA De Novo classification
Trial enrollment expected to begin in Q2 2026, conducted in partnership with Lindus Health

Financial Impact

EPS miss of 27% below expectations; minimal revenue base ($15K consensus)

epsrevenue

Risk Factors

High risk of clinical trial delays or failure
Dependence on regulatory approval via uncertain De Novo pathway
Limited financial runway without clear funding update

Market Snapshot

Exchange

Nasdaq

Sector

Electromedical & Electrotherapeutic Apparatus

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3279086

5 reports for NXL

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for NXL — sortable, filterable
	Type				Now
May 19, 2026 21d ago	8-K MIXED ★ 6/10	$0.3350 $0.5590	▲ +66.87%	▲ +65.63%	$0.5020 (+49.85%)
May 19, 2026 21d ago	Press Release BULLISH ★ 6/10	$0.3210 $0.5063	▲ +57.73%	▲ +55.48%	$0.5020 (+56.39%)
Apr 22, 2026 6w ago	8-K NEUTRAL ★ 5/10	$0.4310 $0.3470	▼ −19.49%	▼ −20.97%	$0.5020 (+16.47%)
Apr 22, 2026 6w ago	Press Release BEARISH ★ 6/10	$0.4700 $0.3699	▲ +21.30%	▲ +21.35%	$0.5020 (−6.81%)
Feb 25, 2026 14w ago	8-K NEUTRAL ★ 4/10	$0.5040 $0.4420	▼ −12.30%	▼ −11.20%	$0.5020 (−0.40%)

US Market Status

Market Closed — Opens in 7h 10m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access